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ABSTRACT
Objective: This article describes the results of an explor-
atory analysis of treatment satisfaction data from a phase
2 study to inform the evaluation of a new treatment for
benign prostatic hyperplasia (BPH).
Methods: The study was a randomized, placebo-
controlled, double blind trial comparing three doses (low,
medium, and high) of a new uro-selective alpha-blocker
with an active comparator. A total of 536 men aged
40 years and older with lower urinary tract symptoms
(LUTS) resulting from BPH were randomized into the
study. Patients’ perceptions of satisfaction with efﬁcacy,
dosing, and side effects were explored using a validated
disease-speciﬁc instrument, the Treatment Satisfaction
Scale—Benign Prostatic Hyperplasia (TSS-BPH). The
TSS-BPH was administered at the end of the study or at
withdrawal.
Results: Compared with placebo, the medium and high
doses showed the greatest efﬁcacy on the primary end-
point, the International Prostate Symptom Score (IPSS).
Patient satisfaction with efﬁcacy at these doses was
signiﬁcantly better than that for placebo. Nevertheless,
adverse events were most frequent in the high dose group.
Satisfaction with side effects was signiﬁcantly worse than
placebo for this group, and this was reﬂected in the total
scores on the TSS-BPH, with patients being most satisﬁed
overall with the medium dose.
Conclusions: Exploring patients’ treatment satisfaction
with medication in early trials using multidimensional
measures provides an overall evaluation of efﬁcacy and
side effects, and can be used to inform the selection of
doses for later trials. This is especially useful for products
that require adherence with medication over long periods
of time.
Keywords: BPH, clinical trials, treatment satisfaction,
urinary symptoms.
Introduction
Benign prostatic hyperplasia (BPH) is a disease of
older men characterized by urinary symptoms
resulting from a nonmalignant enlargement of the
prostate. This enlargement is a normal consequence
of aging [1], but it may be associated with symp-
toms of the lower urinary tract, which, although
rarely life threatening, can be distressing [2].
Pharmacological therapies for the treatment of
urinary symptoms due to BPH include long-term
treatment with agents that decrease resistance to
urinary ﬂow by either decreasing prostatic size (5-
alpha reductase inhibitors) [3] or by relaxing the
smooth-muscle tone of the prostate and bladder
neck (alpha blockers) [4]. Alpha-receptors are
present not only in the prostate, but in various
nonprostatic tissues, in particular vascular,
smooth muscle. Alpha-blockers that are uro-
selective speciﬁcally to those receptors present in
prostatic tissue are likely to have less unwanted
systemic and, particularly, cardiovascular side
effects [5].
Minimizing these side effects is important as
patients’ satisfaction with tolerability, in addition to
efﬁcacy, is known to inﬂuence adherence to medical
regimes [6]. The consequences of poor adherence
may be particularly problematic for patients with
chronic disease conditions like BPH requiring long-
term treatment of symptoms [7,8]. Low adherence
can reduce the effectiveness of a treatment, resulting
in poor management of the patient’s symptoms and
increased burden on the broader health-care system
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[9]. New treatments for a chronic condition like
BPH therefore need to demonstrate differentiation
from competitors not only in terms of efﬁcacy but
also in terms of side effects, with a view to improv-
ing adherence with treatment and ensuring ade-
quate control of symptoms.
Assessment of treatment satisfaction offers an
insight into patients’ perceptions of treatment, pro-
viding an opportunity to evaluate the combined
effect of efﬁcacy and side effects. Exploring
patients’ perception of medication in early trials is
thus useful to inform the selection of doses for later
trials, especially for products used for the treatment
of chronic conditions that require adherence to
medication over long periods of time. This article
describes the results of an exploratory analysis of
domain and total scores on a measure of treatment
satisfaction in a phase 2 study to evaluate a new
treatment for the urinary symptoms resulting from
BPH.
Methods
Study Sample
The study sample was made up of 536 men aged
40 years and older, with lower urinary tract symp-
toms (LUTS) due to benign prostatic obstruction
(BPO), as diagnosed by an International Prostate
Symptom Score (IPSS) of 13 or more and a maxi-
mum ﬂow rate (Q-max) between 5.0 and 15.0 ml/s
with a voided volume more than 150 ml at
screening.
Study Design
The study was a phase 2 randomized, double-blind,
placebo-controlled trial comparing three doses of a
study medication (low, medium, and high) for the
treatment of symptoms associated with LUTS and
an active comparator. The dosing regimen was a
single tablet taken once per day. Sites were located
in the UK, India, Poland, Australia, Estonia, Nor-
way, Finland, Slovakia, Czech Republic, Lithuania,
and South Africa. The study ran for 12 weeks, with
the treatment satisfaction measure, the Treatment
Satisfaction Scale—Benign Prostatic Hyperplasia
(TSS-BPH), being completed at the end of the study
(Week 12) or at withdrawal from the study. The pri-
mary endpoint for the study was a measure of uri-
nary symptom severity—the IPSS. Only the results
for the different doses of the study drug versus pla-
cebo are presented in this article to illustrate the use
of treatment satisfaction data for the evaluation of a
new treatment.
Instruments
The Treatment Satisfaction Scale for men with
Benign   Prostatic   Hyperplasia   (TSS-BPH).
The TSS-BPH was adapted from the Treatment
Satisfaction Module (For Skin), TSM, which was
developed to assess treatment satisfaction in
women taking hormone replacement therapy
(HRT) [10]. The TSS-BPH consists of 13 items,
11 with a ﬁve-point Likert-like response scale and
two with dichotomous (yes/no) response options.
There are three subscales: Satisfaction with Efﬁ-
cacy, Satisfaction with Dosing, and Satisfaction
with Side Effects, plus an Overall score calculated
as the mean of the items. These subscales are
comprised of 10 items that are generic in nature,
for example, “how convenient has it been for you
to take your study medication as directed?” and
three items that are condition-speciﬁc, but are
considered by the original authors of the TSM to
be suitable for modiﬁcation. The TSS is scored
from 0 to 100 with lower scores indicating greater
satisfaction. It is scored in this direction to be
consistent with the primary endpoint, the IPSS,
where a decreasing score is indicative of an
improvement in symptoms.
Traditionally, treatment satisfaction has been
measured using a single item. The TSM was cho-
sen for the study as it has been shown to meas-
ure distinct conceptual elements of treatment
satisfaction (efﬁcacy, dosing, and side effects) and
thus seemed to be more appropriate than a single
item to understand the net evaluation of product
attributes by a patient. To ensure the TSS-BPH
was suitable for a BPH population, it was cogni-
tively debriefed with men with BPH as part of the
linguistic adaptation process before its inclusion in
the trial.
The linguistic validation process was con-
ducted to ensure conceptual and linguistic equiva-
lence of the instrument for use in a number of
countries in Asia, Africa, Europe, and North
America. The methodology used for this process
was the commonly accepted process for the devel-
opment of culturally valid translations of patient
reported outcome measures involving two inde-
pendent forward translations, reconciliation, two
independent back translations, and pilot testing
[11]. The cognitive debrieﬁng was conducted with
65 men who were undergoing treatment for uro-
logical symptoms due to BPH in 13 countries (ﬁve
men in each country) and who were native speak-
ers of the language being tested. The cognitive
debrieﬁng interviews involved respondents being
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asked to complete a copy of the newly translated
TSS-BPH. They were then taken through the ques-
tionnaire item by item while “thinking aloud” to
the interviewer with regards to what they under-
stood each item to mean. The process also ensured
the items were conceptually appropriate for a BPH
population and that they addressed all important
aspects of treatment related to medication for this
condition.
The TSS-BPH has been validated with a male
BPH population and has been found to be psycho-
metrically robust [12]. Good internal consistency
was demonstrated, with alpha coefﬁcients between
0.8 and 0.9. The TSS also demonstrated good con-
struct validity, with signiﬁcant and moderate corre-
lations with the IPSS and a measure of patient
impact, the BPH Patient Impact Measure. Lower
satisfaction was associated with more severe symp-
toms and higher numbers of adverse events. Using
Rasch analysis [13], differential item functioning by
country was also explored during the validation
process. This showed that items were being
answered in a similar manner across countries and
that pooling country data generated by the TSS-
BPH would be appropriate.
The International Prostate Symptom Score (IPSS).
The IPSS 1-week version is a seven-item self-report
questionnaire to assess and evaluate the severity of
LUTS due to BPH [14]. The IPSS is the gold stand-
ard for the measurement of LUTS, and its reliability
and validity has been well documented [15,16]. The
IPSS is scored from 0 to 35 with a higher score indi-
cating greater severity of symptoms.
Statistical Analysis
Data were analyzed using SPSS® Version 11.0. The
graphical data presented in the report were pro-
duced in SPSS (Version 11.5, Troy, NY), and Micro-
soft Excel (Version 2000). Comparisons of TSS
scores for the different treatment groups were
adjusted for age and baseline symptom severity
(IPSS) scores.
Results
Patient Characteristics
The men were aged from 42 to 89, with a mean age
of 64.45 (SD 8.08). Baseline IPSS scores ranged
from 5 to 35, with a mean of 18.55 (SD 4.62).
There were no signiﬁcant differences between treat-
ment arms with regard to age or baseline IPSS
scores. Age was signiﬁcantly related to IPSS scores
(r = −0.09, P < 0.05) with IPSS scores improving
with age. Thirty-nine men withdrew during the
course of the trial, 11 due to adverse events of
which nine were considered by the investigator to
be treatment related.
The International Prostate Symptom Score
The three treatment doses were compared with pla-
cebo using an analysis of covariance (ANCOVA)
adjusting for the covariates of age, total IPSS score at
baseline, country, and treatment. The ANCOVA anal-
ysis of IPSS change at 12 weeks showed that both the
medium and high doses were signiﬁcantly superior
to placebo, with both showing a 2.8-point improve-
ment in IPSS greater than placebo (P < 0.05).
Adverse Events
Treatment emergent adverse events (all causalities)
were most frequent in the high dose group, the two
most common being retrograde ejaculation and
dizziness, both well-known side effects of alpha-
blockers. A total of 14.6% of participants in this
group suffered from retrograde ejaculation com-
pared with 7.2% of participants in the medium dose
group and 0% in the placebo group. Incidences of
dizziness increased with increasing doses with 8%
reporting dizziness in the high dose group, com-
pared with 6.5% in the medium dose group and 4%
in the placebo group.
Treatment Satisfaction
The descriptive and group comparisons are summa-
rized in Table 1, and are discussed in detail as
follows:
Table 1 Treatment satisfaction scores by treatment group
Placebo
n = 65
Mean (SD)
Low dose
n = 127
Mean (SD)
Medium dose
n = 129
Mean (SD)
High dose 
n = 125 
Mean (SD)
Satisfaction with Efﬁcacy 39.11 (18.07) 36.10 (15.09) 31.61 (15.94)* 31.41 (17.91)*
Satisfaction with Dosing 11.54 (9.19) 13.39 (9.86) 9.40 (9.12) 11.90 (9.73)
Satisfaction with Side Effects 6.15 (18.68) 6.77 (18.03) 9.30 (21.66) 18.55 (30.19)*
Overall Satisfaction 30.56 (13.59) 28.77 (11.30) 25.19 (12.28)* 26.64 (14.86)*
Lower scores indicate better satisfaction.
*P < 0.05 versus placebo.
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TSS-BPH domain: satisfaction with efﬁcacy. After
adjusting for age and baseline IPSS score, the scores
on the Satisfaction with Efﬁcacy domain in the
placebo group were signiﬁcantly higher (higher
score = greater dissatisfaction) than patients’ scores
in the medium dose (P = 0.005, conﬁdence interval
[CI] −12.46 to −2.25) and high dose (P = 0.003,
CI −12.99 to −2.71) groups. Thus patients in the
medium and high dose groups were more satisﬁed
with the efﬁcacy of their treatment than patients in
the placebo group (Fig. 1). Participants were most
satisﬁed with efﬁcacy in the high dose group.
TSS-BPH domain: satisfaction with dosing. As
expected, as all the doses were administered in a
similar manner (one tablet, once per day), there
were no statistically signiﬁcant differences in TSS-
BPH Satisfaction with Dosing scores between any of
the study medication groups and placebo. Scores
showed participants in all groups to be highly sat-
isﬁed with dosing, with mean scores ranging from
to 9.39 (SD 9.12) in the medium dose group to
13.39 (SD 9.86) in the low dose group.
TSS-BPH domain: satisfaction with side effects.
Scores on the domain Satisfaction with Side Effects
were highest in the high dose group, with signiﬁ-
cantly more dissatisfaction with regard to side
effects compared with those in the placebo group
(P = 0.001, CI 5.28–18.79). Those in the medium
and low dose groups did not differ from placebo in
terms of Satisfaction with Side Effects. (Fig. 2).
TSS-BPH total: Overall Satisfaction. Adjusting for
age and baseline IPSS score, the TSS-BPH Overall
Satisfaction scores in the medium dose and high
dose groups were lower than those in the placebo
group (P = 0.010, CI −9.20 to −1.28 and P = 0.045,
CI −8.09 to −0.97, respectively) indicating that
overall patient satisfaction was signiﬁcantly better
in the medium dose and high dose study medication
groups compared with placebo (Fig. 3). Those in
the medium dose group had the greatest overall sat-
isfaction, though this was not signiﬁcantly better
than the high dose group. Nevertheless, the unad-
justed analyses showed that only the medium dose
group was signiﬁcantly more satisﬁed than the pla-
cebo group (P = 0.027).
Discussion
One of the aims of early clinical trials is to select
doses for later trials. Nevertheless, this can be dif-
ﬁcult to evaluate, particularly if the dose that pro-
vides the best efﬁcacy also results in the most side
effects. Treatment satisfaction data can make a val-
uable contribution to the assessment of new prod-
ucts, providing a net evaluation from the patient’s
perspective of the efﬁcacy and tolerability of a treat-
ment [17].
In this study, efﬁcacy as measured by the primary
endpoint was seen for patients in both the medium
dose and high dose arms, and this was reﬂected in
the scores on the Satisfaction with Efﬁcacy domain
Figure 1 Mean TSS-BPH Satisfaction with Efﬁcacy scores by treat-
ment (adjusted for age and baseline IPSS score). Lower scores indi-
cate better satisfaction.
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Figure 2 Mean TSS-BPH Satisfaction with Side Effects scores by
treatment (adjusted for age and baseline IPSS score). Lower scores
indicate better satisfaction.
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of the treatment satisfaction measure. As dosing
was similar across all groups in this study, no dif-
ference was expected on Satisfaction with Dosing
domain, and this was what was found. Those in the
high dose group had signiﬁcantly greatest dissatis-
faction in relation to side effects, a reﬂection of the
greater number of adverse events experienced in this
group. As a result of this, combining the items into
a total score showed that overall patients appeared
to be most satisﬁed with the medium dose rather
than the high dose.
By exploring domains of satisfaction it is possible
to understand why one dose, or compound, or
method of administration, is preferred over another.
Nevertheless, the multidimensionality of treatment
satisfaction is often ignored, with a single item often
being used to measure satisfaction [18,19]. This is
usually because of concerns with patient burden, as
patients often complete many questionnaires during
a clinical trial. Nevertheless, use of a single-item can
mean the loss of important information about how
patients view a treatment, as global ratings of sat-
isfaction are often positively skewed, with patients
reporting high levels of satisfaction regardless of
other negative information [20]. A more compre-
hensive measurement of satisfaction can be
obtained by including all the important aspects of
the treatment experience as judged by the patients,
namely efﬁcacy, convenience of dosing and side
effects. Together, the data reported here would sup-
port the selection of the medium dose as one of the
doses to take forward to later trials; it has equiva-
lent efﬁcacy to the higher dose, fewer side effects
and a better satisfaction proﬁle.
Treatment satisfaction assessments are tradition-
ally used in later phase trials to predict adherence or
to support messages regarding the value of the
product to patients. Nevertheless, this study shows
that a greater understanding of the different aspects
contributing to the overall treatment satisfaction
score earlier in drug development can also help deci-
sion making earlier in the development process. In
particular the measurement of treatment satisfac-
tion can inform the design of clinical trials, the
assessment of the viability of the new product in the
commercial setting, and also provide feedback to
scientists working to discover new treatments for
the treatment of urinary symptoms due to BPH for
targeting selective agents aimed at further improv-
ing efﬁcacy and reducing side effects.
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